11. TPC-144, a novel reversible LSD1 inhibitor, exhibited strong antitumor activity in preclinical models of AML and SCLC. (December 2016) Authors: Kawagishi, A.; Yamashita, S.; Hatanaka, R.; Kodama, Y.; Tsuji, S.; Ogawa, T.; Osada, A.; Tanaka, K.; Komatani, H.; Matsuo, K.; Utsugi, T.; Iwasawa, Y. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗